Processa Pharma Files 8-K, Confirms Nasdaq Listing

TL;DR

**PCSA filed a routine 8-K, no new news, just standard compliance.**

AI Summary

Processa Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on the Nasdaq Capital Market under the ticker PCSA. This filing doesn't announce any new financial events, acquisitions, or significant operational changes. For investors, this means there's no immediate new information to impact their investment decisions, but it reaffirms the company's compliance with SEC reporting requirements.

Why It Matters

This filing is a routine disclosure, confirming Processa Pharmaceuticals' listing on the Nasdaq Capital Market, which is important for maintaining investor confidence and market transparency.

Risk Assessment

Risk Level: low — This 8-K is a standard, informational filing with no new material events, indicating a low immediate risk.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate new catalysts or concerns for Processa Pharmaceuticals, Inc. (PCSA). It's a 'no news is good news' scenario for ongoing holders, but doesn't provide new reasons to buy or sell.

Key Numbers

• 001-39531 — Commission file number (identifies the company's registration with the SEC)
• $.0001 — Par value per share (the nominal value assigned to each share of common stock)

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
• Nasdaq Capital Market (company) — the exchange where Processa Pharmaceuticals' common stock is registered
• PCSA (company) — the trading symbol for Processa Pharmaceuticals' common stock
• January 8, 2024 (date) — the date of the earliest event reported and filing date
• 001-39531 (dollar_amount) — the Commission file number
• $.0001 (dollar_amount) — par value of common stock

FAQ

Filing Documents

• form8-k.htm (8-K) — 39KB
• ex99-1.htm (EX-99.1) — 15KB
• ex99-1_001.jpg (GRAPHIC) — 241KB
• ex99-1_002.jpg (GRAPHIC) — 508KB
• ex99-1_003.jpg (GRAPHIC) — 303KB
• ex99-1_004.jpg (GRAPHIC) — 277KB
• ex99-1_005.jpg (GRAPHIC) — 297KB
• ex99-1_006.jpg (GRAPHIC) — 240KB
• ex99-1_007.jpg (GRAPHIC) — 273KB
• ex99-1_008.jpg (GRAPHIC) — 243KB
• ex99-1_009.jpg (GRAPHIC) — 359KB
• ex99-1_010.jpg (GRAPHIC) — 250KB
• ex99-1_011.jpg (GRAPHIC) — 229KB
• ex99-1_012.jpg (GRAPHIC) — 308KB
• ex99-1_013.jpg (GRAPHIC) — 310KB
• ex99-1_014.jpg (GRAPHIC) — 213KB
• ex99-1_015.jpg (GRAPHIC) — 292KB
• ex99-1_016.jpg (GRAPHIC) — 257KB
• ex99-1_017.jpg (GRAPHIC) — 540KB
• 0001493152-24-001713.txt ( ) — 7304KB
• pcsa-20240108.xsd (EX-101.SCH) — 3KB
• pcsa-20240108_lab.xml (EX-101.LAB) — 33KB
• pcsa-20240108_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2024 Commission file number 001-39531 PROCESSA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 45-1539785 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 7380 Coca Cola Drive , Suite 106 , Hanover , Maryland 21076 (Address of Principal Executive Offices, Including Zip Code) (443) 776-3133 (Registrant's Telephone Number, Including Area Code) (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock: Par value $.0001 PCSA Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01. Regulation Disclosure. Mr. George Ng, CEO for Processa Pharmaceuticals, Inc. (" Processa ") will present at the Biotech Showcase 2024 being held January 8-10, 2024 in San Francisco, CA at the Hilton San Francisco Union Square. Mr. Ng's presentation "Next Generation Chemotherapy: Improved Treatment for More Patients" will be held on January 8, 2024 at 1:00 PM PT. Management will be attending the meeting in person and will be available for questions and one-on-one meetings. During the session, Processa's presentation will be uploaded into a portal, which is furnished as Exhibit 99.1 and is incorporated herein by reference. The presentation will also be made available in the "Investors" section on Processa's website, located at https://www.processapharmaceuticals.com . Processa undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases, or through other public disclosure, including in the "Investors" section of Processa's website. Processa routinely uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Processa Pharmaceuticals Presentation dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the iXBRL (Inline eXtensible Business Reporting Language) document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on January 8, 2024. PROCESSA PHARMACEUTICALS, INC. Registrant By: /s/ George Ng George Ng Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR